Johnson & Johnson (JNJ) Shares Bought by Kessler Investment Group LLC
Kessler Investment Group LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,670 shares of the company’s stock after buying an additional 1,835 shares during the period. Johnson & Johnson comprises about 3.6% of Kessler Investment Group LLC’s investment portfolio, making the stock its 9th largest position. Kessler Investment Group LLC’s holdings in Johnson & Johnson were worth $2,507,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of JNJ. Telemus Capital LLC boosted its position in Johnson & Johnson by 24.0% in the second quarter. Telemus Capital LLC now owns 34,757 shares of the company’s stock worth $4,216,000 after buying an additional 6,729 shares during the last quarter. Charter Trust Co. boosted its position in Johnson & Johnson by 2.1% in the second quarter. Charter Trust Co. now owns 202,496 shares of the company’s stock worth $24,562,000 after buying an additional 4,203 shares during the last quarter. St. Johns Investment Management Company LLC boosted its position in Johnson & Johnson by 1.6% in the second quarter. St. Johns Investment Management Company LLC now owns 15,813 shares of the company’s stock worth $1,918,000 after buying an additional 244 shares during the last quarter. D. Scott Neal Inc. boosted its position in Johnson & Johnson by 4.1% in the second quarter. D. Scott Neal Inc. now owns 1,840 shares of the company’s stock worth $223,000 after buying an additional 72 shares during the last quarter. Finally, Pennsylvania Trust Co boosted its position in Johnson & Johnson by 3.4% in the second quarter. Pennsylvania Trust Co now owns 376,563 shares of the company’s stock worth $45,677,000 after buying an additional 12,344 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.59% during trading on Friday, reaching $117.56. The company’s stock had a trading volume of 5,640,519 shares. The firm has a market capitalization of $321.63 billion, a P/E ratio of 21.91 and a beta of 0.62. The company has a 50 day moving average price of $118.72 and a 200 day moving average price of $117.37. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. On average, equities research analysts expect that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
Several equities research analysts have weighed in on the company. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.14 target price for the company in a report on Monday, October 3rd. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Credit Suisse Group AG reiterated a “neutral” rating and issued a $123.00 target price on shares of Johnson & Johnson in a report on Monday, September 19th. Jefferies Group lowered their target price on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 13th. Finally, Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $120.19.
In other news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.